Business
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
Company expands precision oncology pipeline with licensing of CRB-701, clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Company expands precision oncology pipeline with licensing of CRB-701, clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical GroupCRB-701 Phase 1 dose escalation ongoing in China in patients with advanced solid tumorsCRB-601 anti-αvβ8 mAb program scheduled for IND submission in the second half of 2023CRB-601 continues to demonstrate compelling pre-clinical monotherapy and combination data with anti-PD-1Dr. Yong Ben, distinguished oncology researcher joins the Corbus Board of DirectorsNORWOOD, Mass., March 7, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\"Corbus\" or the \"Company\"), a precision oncology company, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2022.\n\n \n \n \n \n \n \n\n \n\"The fourth quarter and recent weeks have been a productive period for Corbus as we continue to evolve into a precision oncology company,\" said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. \"With the execution of our exclusive licensing agreement for CRB-701, a next generation Nectin-4 ADC, we are excited to have a compelling, differentiated asset in the clinic. Concurrently, we continue on-track to the clinic with CRB-601 supported by our latest pre-clinical data presented at SITC 2022\".\nKey Corporate and Program Updates:\nCRB-701 next generation Nectin-4 ADCAcquired CRB-701 through licensing agreement with CSPC Pharmaceutical Group granting exclusive development and commercialization rights in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia.CRB-701 is designed to achieve an improved therapeutic index and patient convenience and could act on a broad range of Nectin-4 expressing tumors.Clinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid tumors potentially including lung, breast and prostate cancer.CRB-601 blocking the activation of TGFβCRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of latent TGFβ within the tumor microenvironment.CRB-601 significantly inhibits tumor growth as a single agent and enhances the efficacy of anti-PD-1 immunotherapy in checkpoint inhibitor (CPI) sensitive and CPI-resistant tumor models.Pre-clinical data presente...